Bioinspired Engineered Virus‐Mimetic Vesicles for Enhanced Cytosolic Delivery of STING Agonists Into Dendritic Cells
Advanced Materials · 2026
DOI: 10.1002/adma.202520019 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, 2026. Verfasst von Shi-Zhen Geng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Pain and Perioperative Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, P. R. China. Hauptthemen laut MEDLINE: Dendritic Cells, Cytosol, Membrane Proteins, Biomimetic Materials. Die Arbeit nennt 46 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Joint Construction Project of the Henan Provincial Medical Science and Technology Research Plan.
Abstract (Originalsprache)
Effective delivery to dendritic cells (DCs) is crucial for the clinical translation of STING agonists, however, current cyclic dinucleotide (CDN) therapies are hindered by inefficient cytosolic delivery and off‐target activation‐induced T cell exhaustion. Here, a high‐fidelity, dengue virus‐mimetic platform (CDN@VLP) is engineered to leverage natural tropism for precise cytosolic release in immature DCs. Compared to conventional lipid nanoparticles, CDN@VLP enhances DC‐specific uptake by 1.9‐fold while reducing non‐specific T cell internalization in tumors by 14.8‐fold, achieving comparable antitumor efficacy at one‐fortieth the dose of free CDN. Systematic screening identifies an optimal VLP subtype that improves targeted accumulation in type 1 conventional DCs (cDC1s)—a subset essential for STING pathway activation—by 2.3‐fold and amplifies durable type I interferon responses, resulting in a 12.8‐fold increase in IFN‐β production. Transcriptomic analysis further reveals that CDN@VLP promotes cDC1 recruitment into tumors by enhancing the secretion of key chemokines (XCL1, CCL4, and CCL5), suggesting an additional mechanism of action. By mimicking viral tropism, the CDN@VLP platform establishes a paradigm for precision STING activation, overcoming the trade‐off between potency and specificity in cDC1‐targeted immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, Pain and Perioperative Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, P. R. China.
- School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, P. R. China.
- Department of Ultrasound, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, P. R. China.
- Department of Anesthesiology and Perioperative Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, P. R. China.
ORCID-Profile: Shi-Zhen Geng, Zhehao Zhang, Jinjin Shi, Yiling Yang, Jian-Jun Yang
Förderung
- National Natural Science Foundation of China
- Joint Construction Project of the Henan Provincial Medical Science and Technology Research Plan
Zitieren
APA
Geng, S. Z., Shi, Y., Yang, J., Gao, Y., Zhang, Z., Wu, H., Liu, P. M., Shi, J., Yang, Y., & Yang, J. J. (2026). Bioinspired Engineered Virus‐Mimetic Vesicles for Enhanced Cytosolic Delivery of STING Agonists Into Dendritic Cells. Advanced Materials. https://doi.org/10.1002/adma.202520019
Vancouver
Geng SZ, Shi Y, Yang J, Gao Y, Zhang Z, Wu H, et al. Bioinspired Engineered Virus‐Mimetic Vesicles for Enhanced Cytosolic Delivery of STING Agonists Into Dendritic Cells. Advanced Materials. 2026. doi:10.1002/adma.202520019
BibTeX
@article{Geng2026,
author = {Geng, Shi-Zhen and Shi, Yaru and Yang, Jinjin and Gao, Yiwen and Zhang, Zhehao and Wu, Hao and Liu, Pan-Miao and Shi, Jinjin and Yang, Yiling and Yang, Jian-Jun},
title = {Bioinspired Engineered Virus‐Mimetic Vesicles for Enhanced Cytosolic Delivery of STING Agonists Into Dendritic Cells},
journal = {Advanced Materials},
year = {2026},
doi = {10.1002/adma.202520019}
}
EUVIMED